The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Novo Nordisk and Ascendis form $285m partnership for once-monthly GLP-1 drug
Nov 07, 2024•over 1 year ago
Contract Type
partnership
BagsværdManufacturing
Description
Novo Nordisk and Ascendis have entered into a partnership to develop and commercialize a once-monthly GLP-1 drug, with an initial upfront payment of $285 million. This partnership aims to leverage Novo Nordisk's expertise in diabetes care and Ascendis's innovative therapies for rare diseases.
Company Information
Company
Novo Nordisk
Location
Bagsværd, Capital Region of Denmark, Denmark
About
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries.
BagsværdManufacturing